2 weeks Ago By Defense World Staff
Sei Investments Co. lifted its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 14.
4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 339,461 shares of the company’s stock after acquiring an additional 42,743 shares during the period. Sei Investments Co.
owned 0.11% of Amneal Pharmaceuticals worth $2,689,000 as of its most recent SEC filing. Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company.
JPMorgan Chase & Co. lifted its stake in shares of Amneal Pharmaceuticals by 149.7% during the third quarter.
JPMorgan Chase & Co. now owns 1,297,094 shares of the company’s stock valued at $10,792,000 after buying an additional 777,568 shares during the period. Barclays PLC boosted its holdings in shares of Amneal Pharmaceuticals by 134.
1% during the third quarter. Barclays PLC now owns 296,384 shares of the company’s stock worth $2,466,000 after purchasing an additional 169,756 shares during the last quarter. State Street Corp grew its position in shares of Amneal Pharmaceuticals by 3.
8% in the third quarter. State Street Corp now owns 3,514,721 shares of the company’s stock valued at $29,242,000 after purchasing an additional 127,753 shares during the period. China Universal Asset Management Co.
Ltd. acquired a new position in Amneal Pharmaceuticals in the fourth quarter valued at $520,000. Finally, Geode Capital Management LLC increased its stake in Amneal Pharmaceuticals by 11.
1% in the third quarter. Geode Capital Management LLC now owns 3,786,671 shares of the company’s stock valued at $31,511,000 after purchasing an additional 378,136 shares during the last quarter. Hedge funds and other institutional investors own 31.
82% of the company’s stock. Amneal Pharmaceuticals Trading Down 5.5 %Shares of NASDAQ AMRX opened at $7.
38 on Friday. The firm has a 50-day moving average of $8.36 and a two-hundred day moving average of $8.
35. The company has a market capitalization of $2.29 billion, a price-to-earnings ratio of -10.
85 and a beta of 1.06. Amneal Pharmaceuticals, Inc.
has a twelve month low of $5.18 and a twelve month high of $9.48.
Amneal Pharmaceuticals (NASDAQ:AMRX – Get Free Report) last issued its quarterly earnings results on Friday, February 28th. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.
15 by ($0.03). The company had revenue of $730.
52 million during the quarter, compared to analysts’ expectations of $708.21 million. Amneal Pharmaceuticals had a negative return on equity of 346.
26% and a negative net margin of 6.88%. During the same period in the prior year, the business posted $0.
14 EPS. As a group, research analysts predict that Amneal Pharmaceuticals, Inc. will post 0.
53 earnings per share for the current year. Analyst Upgrades and DowngradesA number of brokerages recently weighed in on AMRX. Barclays lifted their target price on Amneal Pharmaceuticals from $10.
00 to $11.00 and gave the company an “overweight” rating in a report on Monday, March 3rd. StockNews.
com lowered Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, December 19th. Finally, JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $9.
00 to $12.00 in a report on Monday, February 24th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.
com, the company has an average rating of “Buy” and a consensus price target of $10.80.View Our Latest Report on Amneal PharmaceuticalsInsider ActivityIn other news, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the company’s stock in a transaction that occurred on Friday, March 14th.
The stock was sold at an average price of $8.35, for a total transaction of $41,750,000.00.
Following the completion of the transaction, the insider now directly owns 48,578,209 shares in the company, valued at $405,628,045.15. The trade was a 9.
33 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gautam Patel sold 80,000 shares of the business’s stock in a transaction dated Monday, February 3rd.
The stock was sold at an average price of $8.14, for a total transaction of $651,200.00.
Following the transaction, the director now owns 1,888,886 shares in the company, valued at approximately $15,375,532.04. The trade was a 4.
06 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 5,222,590 shares of company stock worth $43,614,546.
17.46% of the stock is owned by corporate insiders. Amneal Pharmaceuticals Profile (Free Report)Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.
The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.Featured ArticlesFive stocks we like better than Amneal PharmaceuticalsWhat is the Dogs of the Dow Strategy? Overview and ExamplesArcher Aviation’s Africa Deal Could Boost ACHR StockWhat is a buyback in stocks? A comprehensive guide for investorsAre Short Sellers Wrong About These 3 Semiconductor Stocks?What Is WallStreetBets and What Stocks Are They Targeting?Boeing Gets $50B in March Orders—Is BA Stock a Buy Now?.
